Sanjivani Paranteral Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2ua5dlxty0krlns89skuwkcs.pdf

Key Takeaways


HAL Joint Venture: The Near-Term Catalyst

Srivardhan Khemka: "No, it has actually come under what we had estimated to be. We did have quite a few good round of negotiations and we have managed to save a bunch on it."

Product Portfolio & Competitive Moat

Ashwani Khemka: "Our conversion time is faster than anyone in the industry. We are not blacklisted in any of the overseas tenders."

Supply Chain & Input Costs

Srivardhan Khemka: "So on both fronts, we are looking at increasing freight costs to the tune of sometimes 2x to 3x of our regular freight. So the challenges remain, but we are still going through with our supplies."

New Ventures: Prague JV & Infusion Expansion

Srivardhan Khemka: "If we expand into that market, we will probably add on to another facility which might be bigger than what we have right now. So, anything between EUR0.8 crore to EUR1 crore is not something which is difficult to achieve over the course of the next couple of years if everything stabilizes and the demand continues to grow."

Revenue Mix & Geography


Guidance & Commitments

CommitmentSpecificsTimeline
HAL exhibit batchesExhibit batches to beginEnd or first week of December 2024
HAL production startProduction to commenceQ4 FY25
HAL first full revenue quarterFull quarter of revenue contributionQ1 CY25
HAL capacity rampReach 95%-100% utilizationWithin first couple of months of production
Product launches15-20 products launched per year; 6 done, 5 in the worksFY25 (annual target)
Base business capexINR3.5 croresFY25
Base business capexINR5.5 croresFY26
Export portfolio targetReach 280-300 productsNo date (eventual goal)
Prague medium-term revenueEUR0.8 crore to EUR1 crore achievableOver the next couple of years, conditional on stabilization and demand growth

Key Metrics

MetricQ2 FY25
Revenue₹18.1 cr, +29.5% YoY
EBITDA₹3.2 cr, +43% YoY
EBITDA margin17.9%, vs 16.2% in Q2 FY24
Profit after tax₹2.3 cr, +34.6% YoY
H1 FY25 revenue₹34.6 cr, +30% YoY
H1 FY25 EBITDA margin16.4%, vs 16.3% in H1 FY24
Export/domestic mix72%:28%
Dosage mix: injectables/tablets/nutraceuticals50% / 42.6% / 7.4%
Receivables days58 days, increase of 26 days vs Mar 24
Inventory days28 days
Gross block₹28.49 cr as of Sep 24
Debt₹5 cr on books
Cash and cash equivalents₹5.2 cr
Capex incurred (base business, H1 FY25)₹1.46 cr
Expected capex (base business, FY25)₹3.5 cr
Capacity utilization: Bombay plant~70%-75%
Capacity utilization: Dehradun plant~45%
CMO revenue share~9%-10%
Product launches (FY25 to date)6 launches, another 5 in the works
HAL facility peak revenue expectation₹105 cr to ₹110 cr
HAL facility EBITDA margin expectation~19%
Prague business annual top-line estimate€0.35 cr to €0.4 cr
Prague business margin expectation25% to 30%